Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Crossref DOI link: https://doi.org/10.1186/s13058-016-0691-7
Published Online: 2016-03-15
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Krop, Ian E.
Modi, Shanu
LoRusso, Patricia M.
Pegram, Mark
Guardino, Ellie
Althaus, Betsy
Lu, Dan
Strasak, Alexander
Elias, Anthony
Funding for this research was provided by:
Genentech, Inc.
License valid from 2016-03-15